for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ionis Pharmaceuticals Inc

IONS.O

Latest Trade

56.21USD

Change

-0.30(-0.53%)

Volume

1,217,154

Today's Range

55.22

 - 

56.76

52 Week Range

39.32

 - 

73.09

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
56.51
Open
56.45
Volume
1,217,154
3M AVG Volume
16.52
Today's High
56.76
Today's Low
55.22
52 Week High
73.09
52 Week Low
39.32
Shares Out (MIL)
139.70
Market Cap (MIL)
7,852.37
Forward P/E
-104.36
Dividend (Yield %)
--

Next Event

Q3 2020 Ionis Pharmaceuticals Inc Earnings Release

Latest Developments

More

Ionis Reports Q2 2020 Financial Results

Akcea Announces Appointment Of New Chief Medical Officer

Akcea And Ionis Announce Publication Of Clinical Data Of TEGSEDI study

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Industry

Biotechnology & Drugs

Contact Info

2855 Gazelle Ct

CARLSBAD, CA

92010-6670

United States

+1.760.9319200

https://www.ionispharma.com/

Executive Leadership

Stanley T. Crooke

Executive Chairman of the Board of Directors

Brett P. Monia

Chief Executive Officer, Director

Elizabeth L. Hougen

Senior Vice President, Finance and Chief Financial Officer

Patrick R. O'Neil

Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary

Richard S. Geary

Senior Vice President - Development

Key Stats

2.55 mean rating - 20 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.5K

2018

0.6K

2019

1.1K

2020(E)

0.7K
EPS (USD)

2017

-0.050

2018

2.070

2019

2.080

2020(E)

-0.566
Price To Earnings (TTM)
62.63
Price To Sales (TTM)
8.35
Price To Book (MRQ)
5.69
Price To Cash Flow (TTM)
58.27
Total Debt To Equity (MRQ)
58.76
LT Debt To Equity (MRQ)
58.40
Return on Investment (TTM)
4.73
Return on Equity (TTM)
4.03

Latest News

Latest News

BRIEF-Ionis Reports Qtrly Loss Per Share $0.35

* IONIS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS ACHIEVEMENTS

BRIEF-Ionis And Partner Announce Enrollment Completion Of Global Phase 3 Generation Hd1 Study For Huntington's Disease

* IONIS AND PARTNER ANNOUNCE ENROLLMENT COMPLETION OF GLOBAL PHASE 3 GENERATION HD1 STUDY FOR HUNTINGTON'S DISEASE Source text for Eikon: Further company coverage:

BRIEF-Ionis Reports Q4 Earnings Per Share $1.28

* IONIS PROVIDES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

REFILE-IFR US ECM Calendar

Assembly Biosciences (US, biotech) – $85m ABB. 5.15m shares (100% prim) at $16.50 fixed reoffer versus $17.17 last sale. JEFF, SVB, WMB.

EU committee approves Akcea-Ionis drug for rare genetic disease

An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood.

Novartis aims to pump up cardio business with Ionis deal

Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.

BRIEF-Ionis Pharmaceuticals - Announced Partner Roche, also known as Genentech In U.S., enrolled first patient in study of Rg6042 for Huntington's disease

* IONIS PHARMACEUTICALS - ANNOUNCED PARTNER ROCHE, ALSO KNOWN AS GENENTECH IN U.S., ENROLLED FIRST PATIENT IN STUDY OF RG6042 FOR HUNTINGTON'S DISEASE

BRIEF-Ionis Pharmaceuticals Enters New Collaboration With Partner

* IONIS ENTERS NEW COLLABORATION WITH PARTNER TO DEVELOP IONIS-FB-L RX FOR COMPLEMENT-MEDIATED DISEASES

Akcea Therapeutics genetic disease treatment gets FDA approval

Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.

FDA declines to approve Akcea-Ionis genetic disease drug

The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.

U.S. FDA declines to approve Akcea/Ionis genetic disease drug

The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease which causes fat accumulation in the blood.

BRIEF-Ionis Reports Q1 Total Revenue Of $144 Mln Vs $116 Mln

* FOR Q1 OF 2018, BASIC AND DILUTED NET LOSS PER SHARE WERE $0.01 Source text for Eikon: Further company coverage:

Biogen boosts investment in neurology with $1 billion Ionis deal

Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.

BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

* BIOGEN AND IONIS EXPAND STRATEGIC COLLABORATION TO DEVELOP DRUG CANDIDATES FOR A BROAD RANGE OF NEUROLOGICAL DISEASES

Biogen to pay $1 billion to Ionis in new partnership

Drugmaker Biogen Inc said on Friday it would pay Ionis Pharmaceuticals Inc $1 billion in cash as part of a new ten-year agreement to develop medicines for a broad range of neurological diseases including dementia.

Ionis may get up to $300 million in licensing deal with AstraZeneca

Ionis Pharmaceuticals Inc said on Monday a licensing deal for its fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.

Ionis to get up to $300 mln from licensing deal with AstraZeneca

Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties.

BRIEF-Ionis And AstraZeneca Advance New Drug For NASH

* IONIS PHARMACEUTICALS INC - EARNS $30 MLN LICENSE FEE FOR IONIS-AZ6-2.5-L RX

Pfizer's rare heart disease drug succeeds in late-stage study

Pfizer Inc's experimental drug to treat a rare and fatal disease linked to heart failure reduced deaths and need for hospitalizations in a late-stage study.

BRIEF-Ionis Pharmaceuticals Reports Q4 Earnings Per Share of $0.02

* IONIS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up